Skip to main content
Top
Published in: BMC Cancer 1/2022

Open Access 01-12-2022 | NSCLC | Research

Serum cholinesterase may independently predict prognosis in non-small-cell lung cancer

Authors: Hailiang Ran, Jie Ma, Le Cai, Hai Zhou, Zhongqin Yuan, Ying Chen, Wei Chang, Yunchao Huang, Yuanyuan Xiao

Published in: BMC Cancer | Issue 1/2022

Login to get access

Abstract

Background

Serum cholinesterase (ChE) was found to be involved in cancer initiation and progression. However, the survival association between serum ChE and non-small cell lung cancer (NSCLC) has not been extensively discussed. In the present study, we aim to elevate the role of ChE in overall survival (OS) of NSCLC patients.

Methods

A total of 961 histologically confirmed NSCLC patients diagnosed between 2013 and 2018 in a provincial cancer hospital in southwestern China were retrospectively selected. Relevant information, such as histological type, clinical stage, chemotherapy, smoking status, body mass index (BMI), important serum indicators (albumin, neutrophil-to-lymphocyte ratio, ChE), date of death of the patients was extracted from the computerized hospital information system. Univariate and multivariate Cox proportional hazards models were used to determine the association between baseline serum ChE measured at the diagnosis and the OS of NSCLC patients.

Results

The median of baseline ChE (7700 units/liter) was used as a cut-off to dichotomize NSCLC patients. After controlling for possible confounding factors, serum ChE at diagnosis was significantly associated with OS of NSCLC: patients with higher level of ChE were observed a better prognosis (hazard ratio, HR: 0.77, 95% CI: 0.67–0.93, p = 0.006). Subgroup analysis revealed significant ChE-OS association for NSCLC patients: with lower systemic inflammation level (baseline NLR < 2.95, HR: 0.71, 95% CI: 0.56–0.89, p = 0.003), of adenocarcinoma (HR: 0.66, 95% CI: 0.54–0.80, p < 0.001), in advanced stage (HR: 0.77, 95% CI: 0.66–0.92, p < 0.01), and received chemotherapy (HR: 0.75, 95% CI: 0.59–0.96, p < 0.02).

Conclusion

Baseline ChE may have independent prognostic value for NSCLC patients. Longitudinal studies should be performed to corroborate this finding.
Appendix
Available only for authorised users
Literature
2.
go back to reference de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220–33.CrossRef de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220–33.CrossRef
3.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.CrossRef
4.
go back to reference Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet. 2015;385:1206–18.CrossRef Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet. 2015;385:1206–18.CrossRef
5.
go back to reference Cao M, Chen W. Epidemiology of lung cancer in China. Thorac Cancer. 2019;10(1):3–7.CrossRef Cao M, Chen W. Epidemiology of lung cancer in China. Thorac Cancer. 2019;10(1):3–7.CrossRef
6.
go back to reference Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355(9202):479–85.CrossRef Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355(9202):479–85.CrossRef
8.
go back to reference Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. Br Med J. 2010;340:b5569.CrossRef Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. Br Med J. 2010;340:b5569.CrossRef
9.
go back to reference Xiao Y, Lu J, Chang W, Chen Y, Li X, Li D, et al. Dynamic serum alkaline phosphatase is an indicator of overall survival in pancreatic cancer. BMC Cancer. 2019;19(1):785.CrossRef Xiao Y, Lu J, Chang W, Chen Y, Li X, Li D, et al. Dynamic serum alkaline phosphatase is an indicator of overall survival in pancreatic cancer. BMC Cancer. 2019;19(1):785.CrossRef
10.
go back to reference Li G, Wang Z, Xu J, Wu H, Cai S, He Y. The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis. BMC Cancer. 2016;16:249.CrossRef Li G, Wang Z, Xu J, Wu H, Cai S, He Y. The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis. BMC Cancer. 2016;16:249.CrossRef
11.
go back to reference Xiao Y, Yang H, Lu J, Li D, Xu C, Risch HA. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer. BMC Cancer. 2019;19(1):1020.CrossRef Xiao Y, Yang H, Lu J, Li D, Xu C, Risch HA. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer. BMC Cancer. 2019;19(1):1020.CrossRef
12.
go back to reference Kunutsor SK, Apekey TA, Van Hemelrijck M, Calori G, Perseghin G. Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: systematic review and meta-analysis. Int J Cancer. 2015;136(5):1162–70.CrossRef Kunutsor SK, Apekey TA, Van Hemelrijck M, Calori G, Perseghin G. Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: systematic review and meta-analysis. Int J Cancer. 2015;136(5):1162–70.CrossRef
13.
go back to reference Santarpia L, Grandone I, Contaldo F, Pasanisi F. Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle. 2013;1:31–9.CrossRef Santarpia L, Grandone I, Contaldo F, Pasanisi F. Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle. 2013;1:31–9.CrossRef
14.
go back to reference Mitsunaga S, Kinoshita T, Hasebe T, Nakagohri T, Konishi M, Takahashi S, et al. Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. Pancreas. 2008;36(3):241–8.CrossRef Mitsunaga S, Kinoshita T, Hasebe T, Nakagohri T, Konishi M, Takahashi S, et al. Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. Pancreas. 2008;36(3):241–8.CrossRef
15.
go back to reference Kimura S, Soria F, D'Andrea D, Foerster B, Abufaraj M, Vartolomei MD, et al. Prognostic value of serum cholinesterase in non-muscle-invasive bladder Cancer. Clin Genitourin Cancer. 2018;16(6):e1123–32.CrossRef Kimura S, Soria F, D'Andrea D, Foerster B, Abufaraj M, Vartolomei MD, et al. Prognostic value of serum cholinesterase in non-muscle-invasive bladder Cancer. Clin Genitourin Cancer. 2018;16(6):e1123–32.CrossRef
16.
go back to reference Kumar R, Razab S, Prabhu K, Ray S, Prakash B. Serum butyrylcholinesterase and zinc in breast cancer. J Cancer Res Ther. 2017;13(2):367–70.CrossRef Kumar R, Razab S, Prabhu K, Ray S, Prakash B. Serum butyrylcholinesterase and zinc in breast cancer. J Cancer Res Ther. 2017;13(2):367–70.CrossRef
17.
go back to reference Yamamoto M, Saito H, Uejima C, Tanio A, Tada Y, Matsunaga T, et al. Combination of serum albumin and cholinesterase levels as prognostic Indicator in patients ith colorectal Cancer. Anticancer Res. 2019;39(2):1085–90.CrossRef Yamamoto M, Saito H, Uejima C, Tanio A, Tada Y, Matsunaga T, et al. Combination of serum albumin and cholinesterase levels as prognostic Indicator in patients ith colorectal Cancer. Anticancer Res. 2019;39(2):1085–90.CrossRef
18.
go back to reference Martínez-Moreno P, Nieto-Cerón S, Torres-Lanzas J, Ruiz-Espejo F, Tovar-Zapata I, Martínez-Hernández P, et al. Cholinesterase activity of human lung tumours varies according to their histological classification. Carcinogenesis. 2006;27(3):429–36.CrossRef Martínez-Moreno P, Nieto-Cerón S, Torres-Lanzas J, Ruiz-Espejo F, Tovar-Zapata I, Martínez-Hernández P, et al. Cholinesterase activity of human lung tumours varies according to their histological classification. Carcinogenesis. 2006;27(3):429–36.CrossRef
19.
go back to reference Vartolomei MD, D'Andrea D, Chade DC, Soria F, Kimura S, Foerster B, et al. Role of serum cholinesterase in patients treated with salvage radical prostatectomy. Urol Oncol. 2019;37(2):123–9.CrossRef Vartolomei MD, D'Andrea D, Chade DC, Soria F, Kimura S, Foerster B, et al. Role of serum cholinesterase in patients treated with salvage radical prostatectomy. Urol Oncol. 2019;37(2):123–9.CrossRef
20.
go back to reference Layer PG, Willbold E. Novel functions of cholinesterases in development, physiology and disease. Prog Histochem Cytochem. 1995;29(3):1–94.PubMed Layer PG, Willbold E. Novel functions of cholinesterases in development, physiology and disease. Prog Histochem Cytochem. 1995;29(3):1–94.PubMed
21.
go back to reference Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003;4(2):131–8.CrossRef Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003;4(2):131–8.CrossRef
22.
go back to reference Layer PG. Cholinesterases during development of the avian nervous system. Cell Mol Neurobiol. 1991;11(1):7–33.CrossRef Layer PG. Cholinesterases during development of the avian nervous system. Cell Mol Neurobiol. 1991;11(1):7–33.CrossRef
23.
go back to reference Small DH, Michaelson S, Sberna G. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem Int. 1996;28(5–6):453–83.CrossRef Small DH, Michaelson S, Sberna G. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem Int. 1996;28(5–6):453–83.CrossRef
24.
go back to reference Song P, Sekhon HS, Fu XW, Maier M, Jia Y, Duan J, et al. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res. 2008;68(12):4693–700.CrossRef Song P, Sekhon HS, Fu XW, Maier M, Jia Y, Duan J, et al. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res. 2008;68(12):4693–700.CrossRef
25.
go back to reference Muñoz-Delgado E, Montenegro MF, Morote-García JC, Campoy FJ, Cabezas-Herrera J, Kovacs G, et al. The expression of cholinesterases in human renal tumours varies according to their histological types. Chem Biol Interact. 2008;175(1–3):340–2.CrossRef Muñoz-Delgado E, Montenegro MF, Morote-García JC, Campoy FJ, Cabezas-Herrera J, Kovacs G, et al. The expression of cholinesterases in human renal tumours varies according to their histological types. Chem Biol Interact. 2008;175(1–3):340–2.CrossRef
26.
go back to reference Zhao Y, Wang X, Wang T, Hu X, Hui X, Yan M, et al. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology. 2011;53(2):493–503.CrossRef Zhao Y, Wang X, Wang T, Hu X, Hui X, Yan M, et al. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology. 2011;53(2):493–503.CrossRef
27.
go back to reference Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503.CrossRef Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503.CrossRef
28.
go back to reference Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.CrossRef Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.CrossRef
29.
go back to reference Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008;64(9):895–900.CrossRef Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008;64(9):895–900.CrossRef
30.
go back to reference Bi Y, Zhang J, Zeng D, Chen L, Ye W, Yang Q, et al. Cholinesterase is associated with prognosis and response to chemotherapy in advanced gastric Cancer. Pathol Oncol Res. 2021;25(27):580800.CrossRef Bi Y, Zhang J, Zeng D, Chen L, Ye W, Yang Q, et al. Cholinesterase is associated with prognosis and response to chemotherapy in advanced gastric Cancer. Pathol Oncol Res. 2021;25(27):580800.CrossRef
31.
go back to reference Schweitzer N, Kirstein MM, Kratzel AM, Mederacke YS, Fischer M, Manns MP, et al. Second-line chemotherapy in biliary tract cancer: outcome and prognostic factors. Liver Int. 2019;39(5):914–23.CrossRef Schweitzer N, Kirstein MM, Kratzel AM, Mederacke YS, Fischer M, Manns MP, et al. Second-line chemotherapy in biliary tract cancer: outcome and prognostic factors. Liver Int. 2019;39(5):914–23.CrossRef
32.
go back to reference Takeda H, Nishikawa H, Iguchi E, Ohara Y, Sakamoto A, Hatamaru K, et al. Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Mol Clin Oncol. 2013;1(2):241–8.CrossRef Takeda H, Nishikawa H, Iguchi E, Ohara Y, Sakamoto A, Hatamaru K, et al. Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Mol Clin Oncol. 2013;1(2):241–8.CrossRef
33.
go back to reference Xi HJ, Wu RP, Liu JJ, Zhang LJ, Li ZS. Role of acetylcholinesterase in lung cancer. Thorac Cancer. 2015;6(4):390–8.CrossRef Xi HJ, Wu RP, Liu JJ, Zhang LJ, Li ZS. Role of acetylcholinesterase in lung cancer. Thorac Cancer. 2015;6(4):390–8.CrossRef
34.
go back to reference Xu H, Shen Z, Xiao J, Yang Y, Huang W, Zhou Z, et al. Acetylcholinesterase overexpression mediated by oncolytic adenovirus exhibited potent anti-tumor effect. BMC Cancer. 2014;14:668.CrossRef Xu H, Shen Z, Xiao J, Yang Y, Huang W, Zhou Z, et al. Acetylcholinesterase overexpression mediated by oncolytic adenovirus exhibited potent anti-tumor effect. BMC Cancer. 2014;14:668.CrossRef
35.
go back to reference Lu L, Zhang X, Zhang B, Wu J, Zhang X. Synaptic acetylcholinesterase targeted by microRNA-212 functions as a tumor suppressor in non-small cell lung cancer. Int J Biochem Cell Biol. 2013;45(11):2530–40.CrossRef Lu L, Zhang X, Zhang B, Wu J, Zhang X. Synaptic acetylcholinesterase targeted by microRNA-212 functions as a tumor suppressor in non-small cell lung cancer. Int J Biochem Cell Biol. 2013;45(11):2530–40.CrossRef
Metadata
Title
Serum cholinesterase may independently predict prognosis in non-small-cell lung cancer
Authors
Hailiang Ran
Jie Ma
Le Cai
Hai Zhou
Zhongqin Yuan
Ying Chen
Wei Chang
Yunchao Huang
Yuanyuan Xiao
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2022
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-022-09212-0

Other articles of this Issue 1/2022

BMC Cancer 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine